Citizens raised the firm’s price target on MBX Biosciences (MBX) to $86 from $76 and keeps an Outperform rating on the shares. MBX Biosciences reported encouraging early data for MBX 4291 and canvuparatide, highlighting strong efficacy, monthly or weekly dosing potential, and favorable tolerability, which supports significant upside to the company’s current valuation across both hypoparathyroidism and obesity indications, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- MBX Biosciences price target raised to $70 from $50 at Truist
- MBX Biosciences Phase 1 data supports once-monthly dosing for MBX 4291
- MBX Biosciences Highlights Positive Phase 1 Obesity Data
- Advancing Pipeline and Key Data Catalysts Drive Analyst’s Bullish View on MBX
- MBX Biosciences reports Q1 EPS (51c), consensus (58c)